Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 298

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 298
---
 into the consideration receivable by holders of the underlying shares of common stock, based upon the
value of the shares of the successor entity over a specified period or (ii) cash in an amount equal to the Black-Scholes value.

Series C Warrants

Except as set forth below,
the Series C Warrants have terms and provisions that are substantially the same as those of the Series A Warrants.

Exercise Price. The
Series C Warrants will initially be exercisable for cash at an exercise price equal to $0.098. The exercise price is subject to adjustment
for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares of Common Stock
issuable upon the exercise of the Series C Warrant will also be adjusted so that the aggregate exercise price shall be the same immediately
before and immediately after any such adjustment. Following receipt of shareholder approval of the issuance of shares upon exercise of
the Series C Warrants, which was obtained on November 11, 2024, the exercise price of the Series C Warrants is also subject to a reduction
upon certain issuances of securities at an effective price below such exercise price.

Warrants Issued on December 23, 2024

Except as set forth below,
such warrants have terms and provisions that are substantially the same as those of the Series A Warrants.

Exercise Price. The
warrants issued on December 23, 2024 will initially be exercisable for cash at an exercise price equal to $5.61. The exercise price is
subject to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number
of shares of Common Stock issuable upon the exercise of such warrant will also be adjusted so that the aggregate exercise price shall
be the same immediately before and immediately after any such adjustment. However, unlike the Series A Warrants and Series C Warrants,
the warrants issued on December 23, 2024 are not subject to any exercise price reduction or adjustment relating to the timing of shareholder
approval thereof or the pricing of any future offering.

Warrants Issued on January 6, 2025

Except as set forth below,
such warrants have terms and provisions that are substantially the same as those of the Series A Warrants.

<div align='center'>174</div>

Exercise Price. The
warrants issued on January 6, 2025 will initially be exercisable for cash at an exercise price equal